Heart failure & cardiomyopathies
Intermittent Inotropic Support with Levosimendan in Advanced Heart Failure as Destination Therapy: The LEVO-D Registry
Authors' conclusion
In this large real-life series of AHF patients treated with levosimendan as destination therapy, we show a significant decrease of heart failure events during the year after the first administration.
Study context
- Population
- Patients with advanced HF, not HT or LVAD candidates, on optimal medical therapy, treated with intermittent levosimendan as destination therapy
- Participants
- 403 patients
- Exposure
- Year after vs year before first levosimendan administration
- Outcome
- HF events, year after vs year before levosimendan
- Follow-up
- 1 year
Methodological detailsmulticentre, registry
- Multicentre
- Registry
Main finding
As reported in the abstract
HF admissions
P < 0.0001
Unplanned HF visits
P < 0.0001
Combined event incl. deaths
- Year after vs Year before: P < 0.0001 — combined event including deaths
Observational data: associations, not effects.
Further findings
LEVO-D score for responder status · 1 year
- LEVO-D score for responder status: values = free of death or HF event at 1 year
Mortality and survival · 1 year
- Death rate at 1 year
- 26.8%
- Median survival
- 24.7 months (95% CI 20.4-26.9)
Responders (no death, HF admission or unplanned HF visit at 1 year)
- Responders
- 43.7%
LEVO-D score for responder status · 1 year
- Score items: TEER (+2), beta-blockers (+1.5), Hb >12 g/dL (+1.5), amiodarone (−1.5), HF visit 1 year before (−1.5), heart rate >70 b.p.m. (−2)
- LEVO-D score performed well in ROC analysis
Original publication
Intermittent Inotropic Support with Levosimendan in Advanced Heart Failure as Destination Therapy: The LEVO-D Registry. ESC Heart Fail. Published 19 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →